tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Kyverna Therapeutics price target raised to $33 from $25 at Morgan Stanley
PremiumThe FlyKyverna Therapeutics price target raised to $33 from $25 at Morgan Stanley
16h ago
Kyverna Therapeutics: Promising Outlook with Breakthrough CAR-T Therapy in Autoimmune Diseases
Premium
Ratings
Kyverna Therapeutics: Promising Outlook with Breakthrough CAR-T Therapy in Autoimmune Diseases
18h ago
Midday Fly By: Intel eyes SambaNova, Cencora to acquire OneOncology
Premium
The Fly
Midday Fly By: Intel eyes SambaNova, Cencora to acquire OneOncology
18h ago
Kyverna Therapeutics announces topline data from registrational KYSA-8 trial
PremiumThe FlyKyverna Therapeutics announces topline data from registrational KYSA-8 trial
24h ago
Kyverna Therapeutics price target raised to $25 from $20 at Morgan Stanley
Premium
The Fly
Kyverna Therapeutics price target raised to $25 from $20 at Morgan Stanley
12d ago
Kyverna Therapeutics, Inc.: A Promising Market Position with KYV-101’s Potential as the First FDA-Approved CAR-T Therapy for Autoimmune Diseases
Premium
Ratings
Kyverna Therapeutics, Inc.: A Promising Market Position with KYV-101’s Potential as the First FDA-Approved CAR-T Therapy for Autoimmune Diseases
22d ago
KYTX Earnings this Week: How Will it Perform?
PremiumPre-EarningsKYTX Earnings this Week: How Will it Perform?
1M ago
Kyverna Therapeutics Secures $150 Million Loan Facility
Premium
Company Announcements
Kyverna Therapeutics Secures $150 Million Loan Facility
1M ago
Kyverna Therapeutics secures up to $150M in non-dilutive financing
Premium
The Fly
Kyverna Therapeutics secures up to $150M in non-dilutive financing
1M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100